Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Immunogenicity of a Single Dose of the Lyophilized Formulation of Merck Staphylococcus aureus Vaccine (V710) in Healthy Adults.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs V-710 (Primary)
- Indications Staphylococcal infections
- Focus Pharmacodynamics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 19 Dec 2011 Results published in Vaccine.
- 18 Nov 2011 Additional location (USA) added as reported by ClinicalTrials.gov.
- 22 Jan 2009 New trial record.